The issue of BRAF inhibitors having some potency against CRAF is well recognized for clinically used compounds[ 2 ], and the observed activity of IPA3 may be significant if it proceeds either through BRAF or CRAF inhibition.
← all excerpts
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.
1
—
—